Olpasiran (sodium)
Olpasiran sodium is a small interfering RNA that reduces lipoprotein (a) synthesis in the liver.
Product Specifications
Product Name Alternative
AMG 890 (sodium) ; ARC-LPA (sodium)
UNSPSC
12352208
Target
Small Interfering RNA (siRNA)
Type
Oligonucleotides
Related Pathways
Epigenetics
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/olpasiran-sodium.html
Purity
98.82
Solubility
10 mM in H2O
Smiles
[Olpasiran(sodium)]
Molecular Formula
C490H610F11N164Na42O306P41S7
Molecular Weight
15438.7 (free acid)
References & Citations
[1]Sohn W, Winkle P, Neutel J, et al. Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study. Clin Ther. 2022;44 (9) :1237-1247. |[2]O'Donoghue ML, G López JA, Knusel B, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a) -DOSE) . Am Heart J. 2022;251:61-69.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Badge
Hot
Scientific Category
Oligonucleotides
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
